Patrik Kloos
Management of von Hippel-Lindau Disease: An Interdisciplinary Review
Schmid S, Rothermundt C, Weber J, van Leyen K, Sulz M, Stöckli S, Krull I, Krek W, Kloos P, Heinimann K, Hader C, Greiner J, Engeler D, Brändle M, Binet F, Gillessen Sommer S, Hundsberger T. Management of von Hippel-Lindau Disease: An Interdisciplinary Review. Oncol Res Treat 2014; 37:761-771.
17.11.2014Management of von Hippel-Lindau Disease: An Interdisciplinary Review
17.11.2014Oncol Res Treat 2014; 37:761-771
Schmid Sabine, Rothermundt Christian, Weber Johannes, van Leyen Karin, Sulz Michael, Stöckli Sandro, Krull Ina, Krek Willy, Kloos Patrik, Heinimann Karl, Hader Claudia, Greiner Jeannette, Engeler Daniel, Brändle Michael, Binet Françoise-Isabelle, Gillessen Sommer Silke, Hundsberger Thomas
New guidelines in the treatment of persistent central serous chorioretinopathy: PDT with half-dose verteporfin
Böni C, Kloos P, Valmaggia C, Department of Ophthalmology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland. New guidelines in the treatment of persistent central serous chorioretinopathy: PDT with half-dose verteporfin. Klin Monbl Augenheilkd 2012; 229:327-30.
11.04.2012New guidelines in the treatment of persistent central serous chorioretinopathy: PDT with half-dose verteporfin
11.04.2012Klin Monbl Augenheilkd 2012; 229:327-30
Böni C, Kloos Patrik, Valmaggia Christophe, Department of Ophthalmology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
[Photodynamic therapy in "Secondary Sick RPE Syndrome" after repeated intravitreal injections of VEGF inhibitors in patients with wet age-related macular degeneration]
Kloos P, Niederberger H, Valmaggia C. [Photodynamic therapy in "Secondary Sick RPE Syndrome" after repeated intravitreal injections of VEGF inhibitors in patients with wet age-related macular degeneration]. Klin Monbl Augenheilkd 2011; 228:340-4.
11.04.2011[Photodynamic therapy in "Secondary Sick RPE Syndrome" after repeated intravitreal injections of VEGF inhibitors in patients with wet age-related macular degeneration]
11.04.2011Klin Monbl Augenheilkd 2011; 228:340-4
Kloos Patrik, Niederberger Hugo, Valmaggia Christophe
The treatment of choroidal neovascularizations in age-related macular degeneration using either Avastin or Lucentis
Valmaggia C, Haueter I, Kloos P, Lang C, Niederberger H. The treatment of choroidal neovascularizations in age-related macular degeneration using either Avastin or Lucentis. Klinische Monatsblätter für Augenheilkunde 2009; 226:294-8.
01.04.2009The treatment of choroidal neovascularizations in age-related macular degeneration using either Avastin or Lucentis
01.04.2009Klinische Monatsblätter für Augenheilkunde 2009; 226:294-8
Valmaggia Christophe, Haueter Ilze, Kloos Patrik, Lang C, Niederberger Hugo
Obstructive sleep apnea in patients with central serous chorioretinopathy
Kloos P, Laube I, Thoelen A. Obstructive sleep apnea in patients with central serous chorioretinopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie 2008; 246:1225-8.
01.09.2008Obstructive sleep apnea in patients with central serous chorioretinopathy
01.09.2008Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie 2008; 246:1225-8
Kloos Patrik, Laube Irene, Thoelen Adelheid
The treatment of choroidal neovascularisation with intravitreal injections of bevacizumab (Avastin)
Valmaggia C, Niederberger H, Lang C, Kloos P, Haueter I. The treatment of choroidal neovascularisation with intravitreal injections of bevacizumab (Avastin). Klinische Monatsblätter für Augenheilkunde 2008; 225:380-4.
01.05.2008The treatment of choroidal neovascularisation with intravitreal injections of bevacizumab (Avastin)
01.05.2008Klinische Monatsblätter für Augenheilkunde 2008; 225:380-4
Valmaggia Christophe, Niederberger Hugo, Lang C, Kloos Patrik, Haueter Ilze
[Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration]
Kloos P, Bernasconi P, Estermann S, Bachmann B, Rutishauser Y, Thölen A. [Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration]. Klin Monbl Augenheilkd 2008; 225:385-91.
01.05.2008[Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration]
01.05.2008Klin Monbl Augenheilkd 2008; 225:385-91
Kloos Patrik, Bernasconi P, Estermann S, Bachmann B, Rutishauser Y, Thölen A
Physiologically assessed coronary collateral flow and adverse cardiac ischemic events: a follow-up study in 403 patients with coronary artery disease
Billinger M, Kloos P, Eberli F, Windecker S, Meier B, Seiler C. Physiologically assessed coronary collateral flow and adverse cardiac ischemic events: a follow-up study in 403 patients with coronary artery disease. Journal of the American College of Cardiology 2002; 40:1545-50.
06.11.2002Physiologically assessed coronary collateral flow and adverse cardiac ischemic events: a follow-up study in 403 patients with coronary artery disease
06.11.2002Journal of the American College of Cardiology 2002; 40:1545-50
Billinger Michael, Kloos Patrik, Eberli Franz R, Windecker Stephan, Meier Bernhard, Seiler Christian
Novel silent variant (c1722G>A) in the coding region of the insulin receptor substrate 1 (IRS1) gene
Kloos P, Mergenthaler S, Ranke M, Wollmann H, Eggermann T. Novel silent variant (c1722G>A) in the coding region of the insulin receptor substrate 1 (IRS1) gene. Human mutation 2000; 16:533.
01.12.2000Novel silent variant (c1722G>A) in the coding region of the insulin receptor substrate 1 (IRS1) gene
01.12.2000Human mutation 2000; 16:533
Kloos Patrik, Mergenthaler S, Ranke M B, Wollmann H A, Eggermann T